Literature DB >> 15572102

Report of a collaborative study to calibrate the Second International Standard for parvovirus B19 antibody.

Morag Ferguson1, Alan Heath.   

Abstract

A collaborative study was undertaken to assess the suitability of a replacement for the First International Standard for parvovirus B19 IgG, human serum and to calibrate it in IU. The proposed standard, which is a pool of sera from 16 US blood donors, was assayed along with the First International Standard, a coded duplicate of the proposed standard and a plasma sample from a single blood donor. Nine laboratories from eight countries participated in the studies and five different assay kits were used. Two kits contained VP1+VP2, one kit contained VP1 only and two kits, one of which was used by five participants contained VP2 only. Differences in detection of the proposed standard and the individual plasma were observed with assay kits containing different antigens, VP1, VP2 or VP1+VP2. However, since VP1 is a minor capsid protein and on its own does not assemble into virus like particles and the dominant response in individuals appears to be against VP2, it was considered reasonable to utilize only the data from kits containing VP2 antigen for the calibration of the proposed standard. The results of this study demonstrated that the proposed standard coded 01/602 was suitable to serve as the replacement International Standard for parvovirus B19, serum IgG, and this preparation was established as the Second International Standard for parvovirus B19 antibody, plasma human, with an assigned unitage of 77 IU per ampoule by the Expert Committee on Biological Standardisation of the World Health Organisation in February 2003.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15572102     DOI: 10.1016/j.biologicals.2004.09.004

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  8 in total

Review 1.  Parvovirus B19 infection in human pregnancy.

Authors:  R F Lamont; J D Sobel; E Vaisbuch; J P Kusanovic; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2010-10-13       Impact factor: 6.531

2.  Parvovirus B19 - Revised.

Authors:  Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Georg Pauli; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen; Carl-Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2010-11-17       Impact factor: 3.747

3.  Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection.

Authors:  J Mossong; N Hens; V Friederichs; I Davidkin; M Broman; B Litwinska; J Siennicka; A Trzcinska; P VAN Damme; P Beutels; A Vyse; Z Shkedy; M Aerts; M Massari; G Gabutti
Journal:  Epidemiol Infect       Date:  2007-10-24       Impact factor: 2.451

4.  Reproducibility of serologic assays for influenza virus A (H5N1).

Authors:  Iain Stephenson; Alan Heath; Diane Major; Robert W Newman; Katja Hoschler; Wang Junzi; Jacqueline M Katz; Jerry P Weir; Maria C Zambon; John M Wood
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

5.  Seroprevalence of parvovirus B19 in the German population.

Authors:  C Röhrer; B Gärtner; A Sauerbrei; S Böhm; B Hottenträger; U Raab; W Thierfelder; P Wutzler; S Modrow
Journal:  Epidemiol Infect       Date:  2008-01-16       Impact factor: 2.451

6.  The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa.

Authors:  Chabo Byaene Alain; Lufimbo Katawandja Antoine; Bizeti Nsangu Bizette; Pambu Dahlia; Tshibuela Beya Dophie; Muwonga Masidi Jérémie; Kayembe Nzongola-Nkasu Donatien; Ahuka Mundeke Steve
Journal:  Pan Afr Med J       Date:  2020-03-10

7.  Influence of sample collection tube method, anticoagulant-containing plasma versus serum, on influenza virus hemagglutination inhibition titer and microneutralization titer serological assays.

Authors:  Brian J Morrison; Nicholas J Martin; Tauseef Rehman; Dan Ewing; Robin L Dewar; Julia Metcalf; Peifang Sun; John Beigel; Thomas C Luke; Kanakatte Raviprakash
Journal:  BMC Health Serv Res       Date:  2018-08-22       Impact factor: 2.655

8.  Animal models and antibody assays for evaluating candidate SARS vaccines: summary of a technical meeting 25-26 August 2005, London, UK.

Authors:  Anjeanette Roberts; John Wood; Kanta Subbarao; Morag Ferguson; David Wood; Thomas Cherian
Journal:  Vaccine       Date:  2006-07-18       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.